On July 28, Annovis Bio (NYSE:ANVS) released new clinical and biomarker data from their two phase 2a trials in Alzheimer Disease (AD) and Parkinson Disease (PD) at the 2021 AAIC (Alzheimer's Association International Conference).
For anyone new to ANVS, I
Analyst’s Disclosure:I/we have a beneficial long position in the shares of ANVS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
My articles are not investment recommendations, and I am not an investment adviser. Small/micro cap, clinical stage biotech stocks are highly volatile, speculative, and risky. No clinical trial is guaranteed to succeed, even with strong science, prior positive results, or bullish SA articles. When a trial fails (and the company stops the program), small/micro cap biotech stock can decline very significantly. Also, since these companies have negative revenue, the financial risks such as dilution or insolvency are always present. Investing in these stocks may result in a partial or complete loss of investment. Conduct your own due diligence before making any investment decision. You are responsible for your own investment decisions.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
